American journal of nephrology · 2026
Safety and Effectiveness of Apixaban versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Mingyue, Erickson Kevin F, Kassem Hania, Montez-Rath Maria E, Chang Tara I, Winkelmayer Wolfgang C, Niu Jingbo
Аннотация
INTRODUCTION: Apixaban reduces thromboembolic events, bleeding, and mortality compared with warfarin in patients with nonvalvular atrial fibrillation (NVAF). However, evidence in patients with kidney failure (KF) receiving peritoneal dialysis (PD) is limited. We evaluated the safety and effectiveness of apixaban versus warfarin in this population.
METHODS: Using the US Renal Data System, we identified Medicare beneficiaries on PD with newly diagnosed NVAF (2014-2019) who had no prior oral anticoagulation (OAC) use. We included patients initiating apixaban or warfarin within 30 days after NVAF diagnosis. After propensity matching, we estimated the hazard ratios for thromboembolic events, bleeding events, and mortality using Cox models accounting for competing risks, where applicable, and using both intent-to-treat and as-treated (AT) approaches.
RESULTS: Among 6,571 OAC-naive PD patients with newly diagnosed NVAF, 334 initiated apixaban and 717 initiated warfarin within 30 days. After 1:1 propensity matching, all observed characteristics of 330 apixaban and 330 warfarin users were balanced. The median CHA2DS2-VASc score was 4 (IQR 3-5). In intent-to-treat analyses, hazards of ischemic stroke (hazard ratio [HR] = 0.92; 95% CI: 0.42-2.01) and the composite of other thromboembolic outcomes with cardiovascular death (HR = 0.90; 95% CI: 0.66-1.22) did not differ between groups. The hazards of clinically important bleeding (HR = 0.81; 95% CI: 0.62-1.07), major bleeding, intracranial hemorrhage, and all-cause mortality also did not differ between groups. Findings were consistent in AT analyses.
CONCLUSION: Among PD patients with newly diagnosed NVAF, we observed no statistically significant differences between apixaban and warfarin for effectiveness or bleeding outcomes. Given the challenges of warfarin management in KF, apixaban may represent a more practical option when anticoagulation is pursued.
METHODS: Using the US Renal Data System, we identified Medicare beneficiaries on PD with newly diagnosed NVAF (2014-2019) who had no prior oral anticoagulation (OAC) use. We included patients initiating apixaban or warfarin within 30 days after NVAF diagnosis. After propensity matching, we estimated the hazard ratios for thromboembolic events, bleeding events, and mortality using Cox models accounting for competing risks, where applicable, and using both intent-to-treat and as-treated (AT) approaches.
RESULTS: Among 6,571 OAC-naive PD patients with newly diagnosed NVAF, 334 initiated apixaban and 717 initiated warfarin within 30 days. After 1:1 propensity matching, all observed characteristics of 330 apixaban and 330 warfarin users were balanced. The median CHA2DS2-VASc score was 4 (IQR 3-5). In intent-to-treat analyses, hazards of ischemic stroke (hazard ratio [HR] = 0.92; 95% CI: 0.42-2.01) and the composite of other thromboembolic outcomes with cardiovascular death (HR = 0.90; 95% CI: 0.66-1.22) did not differ between groups. The hazards of clinically important bleeding (HR = 0.81; 95% CI: 0.62-1.07), major bleeding, intracranial hemorrhage, and all-cause mortality also did not differ between groups. Findings were consistent in AT analyses.
CONCLUSION: Among PD patients with newly diagnosed NVAF, we observed no statistically significant differences between apixaban and warfarin for effectiveness or bleeding outcomes. Given the challenges of warfarin management in KF, apixaban may represent a more practical option when anticoagulation is pursued.